國家衛生研究院 NHRI:Item 3990099045/4630
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 922312      在线人数 : 1280
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/4630


    题名: Pharmacoeconomic analysis of capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX) in the first line treatment of metastasis colorectal cancer in Taiwan
    作者: Chen, HH;Chang, CS;Chen, LT;Chen, WT;Hsu, TC;Wang, JY;Wen, CY
    贡献者: National Institute of Cancer Research
    摘要: OBJECTIVES: Colorectal cancer (CRC) is the second most commonly diagnosed cancer and the third cause of cancer-related mortality in Taiwan. Capecitabine (Xeloda ® ), an oral fluoropyrimidine, is an effective alternative to intravenous fluoro-uracil plus leucovorin (5-FU/LV) in treatment of metastasis colon cancer (mCRC). Recently, the addition of oxaliplatin to 5-FU/LV (FOLFOX) or capecitabine (XELOX) have been proven in significantly improving the progression free survival and overall survival compared with single agent. Based on the result of study NO16966 (Cassidy 2007), there is no difference in efficacy between XELOX and FOLFOX. The objective of this study was to develop a pharmacoeconomic model to estimate the medical resource utilization (MRU) of XELOX vs. FOLFOX as first line treatment of mCRC from the payer’s [Bureau of National Health Insurance (BNHI)] perspective. METHODS: A cost-minimization model was constructed to represent the real MRU of XELOX and FOLFOX. Local treatment regimens and drugs administration pat-terns were based on the results of expert panel survey conducted among 13 colorectal surgeons and medical oncologists. Clinical outcomes and adverse events (AEs) inci-dence were referred to the result of study NO16996. Unit costs were estimated from BNHI fee schedules and local expert opinion. Sensitivity analyses were performed on key model parameters. RESULTS: The result showed drug cost was estimated to be higher in the XELOX (NTD$259,618 vs. NTD$204,442) by 6 months. However, these cost increments were offset by the drug administration cost and AEs management cost of FOLFOX. The drug administration cost and AEs management cost in the FOLFOX and XELOX were NTD$119,285 vs. NTD$24,090 and NTD$14,414 vs. NTD$7,155, respectively. FOLFOX regimen required more physician visits, drug infusion times and hospitalizations. As a result, XELOX demonstrated a significant overall cost savings of NTD$47,277. CONCLUSIONS: From the perspective of Taiwan BNHI, this study showed that XELOX is cost-saving in comparison with FOLFOX in the first line treatment of mCRC.
    日期: 2009-10
    關聯: Value in Health. 2009 Oct;12(7):A278.
    Link to: http://dx.doi.org/10.1111/j.1524-4733.2009.00592_2.x
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1098-3015&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000269878100289
    显示于类别:[陳立宗] 會議論文/會議摘要

    文件中的档案:

    档案 描述 大小格式浏览次数
    ISI000269878100289.pdf67KbAdobe PDF268检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈